An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia (PERFlexS)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Janssen-Cilag International NV
ClinicalTrials.gov Identifier:
NCT00460512
First received: April 13, 2007
Last updated: June 13, 2014
Last verified: June 2014
  Purpose

The purpose of this study is to explore tolerability, safety and effectiveness of flexibly dosed paliperidone extended release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) previously unsuccessfully treated with an oral antipsychotic medication.


Condition Intervention Phase
Schizophrenia
Drug: Paliperidone ER
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia

Resource links provided by NLM:


Further study details as provided by Janssen-Cilag International NV:

Primary Outcome Measures:
  • Percentage of Participants With at Least 20 Percent Improvement in Total Positive and Negative Syndrome Scale (PANSS) Score in Those Participants who Transitioned due to Lack of Efficacy [ Time Frame: Endpoint (up to Week 26) ] [ Designated as safety issue: No ]
    The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self). The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent) to 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity.

  • Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint (up to Week 26) [ Time Frame: Baseline and endpoint (up to Week 26) ] [ Designated as safety issue: No ]
    The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent) to 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity.


Secondary Outcome Measures:
  • Percentage of Participants With at Least 20 Percent Improvement in Total Positive and Negative Syndrome Scale (PANSS) Score [ Time Frame: Endpoint (up to Week 26) ] [ Designated as safety issue: No ]
    The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self). The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent) to 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity.

  • Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Subscale Scores at Endpoint (up to Week 26) [ Time Frame: Baseline and endpoint (up to Week 26) ] [ Designated as safety issue: No ]
    The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent) to 7 (extreme). Positive subscale score ranges from 7 (absent) to 49 (extreme psychopathology), negative subscale score ranges from 7 (absent) to 49 (extreme psychopathology) and general psychopathology subscale score ranges from 16 (absent) to 112 (extreme psychopathology).

  • Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Subscale Scores at Endpoint (up to Week 26) [ Time Frame: Baseline and endpoint (up to Week 26) ] [ Designated as safety issue: No ]
    The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Marder PANSS subscales include positive symptoms subscale consisting of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consisting of 7 items with total score range of 7-49; and uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consisting of 4 items with total score range of 4-28. Higher score indicates greater severity.

  • Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Endpoint (up to Week 26) [ Time Frame: Baseline and endpoint (up to Week 26) ] [ Designated as safety issue: No ]
    The CGI-S rating scale assesses the severity of a participant's psychotic condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe).

  • Change From Baseline in Total Personal and Social Performance (PSP) Score at Endpoint (up to Week 26) [ Time Frame: Baseline and endpoint (up to Week 26) ] [ Designated as safety issue: No ]
    The PSP scale assesses the degree of dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; less or equal to 30, functioning so poorly as to require intensive supervision.

  • Change From Baseline in Short-Form 36 Health Survey (SF-36) Score at Endpoint (up to Week 26) [ Time Frame: Baseline and endpoint (up to Week 26) ] [ Designated as safety issue: No ]
    The SF-36 is a health status survey with 36 questions measuring 8 dimensions (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) that are subsequently aggregated into 2 summary scales, Physical Component Summary (PCS) and Mental Component Summary (MCS). Each item is scored into on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state.

  • Number of Participants With Satisfaction With the Study Treatment [ Time Frame: Endpoint (up to Week 26) ] [ Designated as safety issue: No ]
    Participants will assess their satisfaction with paliperidone ER on a 5-point scale: 1 (very good), 2 (good), 3 (moderate), 4 (poor) and 5 (very poor).

  • Change From Baseline in Sleep and Daytime Drowsiness Evaluation Score at Endpoint (up to Week 26) [ Time Frame: Baseline and endpoint (up to Week 26) ] [ Designated as safety issue: No ]
    The Sleep and Daytime Drowsiness Evaluation Scale is a self-administered scale that rates quality of sleep and daytime drowsiness. Participants indicate on an 11 point scale how well they have slept in the previous 7 days, score ranging from 0 (very badly) to 10 (very well) and how often they have felt drowsy within the previous 7 days, score ranging from 0 (not at all) to 10 (all the time).

  • Change From Baseline in Extrapyramidal Symptoms Rating Scale (ESRS) Total Score at Endpoint (up to Week 26) [ Time Frame: Baseline and endpoint (up to Week 26) ] [ Designated as safety issue: No ]
    The ESRS scale assesses parkinsonism (slow movements), dystonia (abnormal muscle movement causing focal/generalized, sustained muscle contractions, postures, and involuntary movements) and dyskinetic (involuntary muscle contractions) movement subscale. Parkinsonism consists of 8 items rated on a 7-point scale (0=absent/normal and 6=worst score), Dystonia consists of 2 items rated on a 7-point scale (0=absent and 6=extremely severe) and Dyskinetic movements consists of 7 items rated on a 7-point scale (0=none and 6=worst score). Total score: 0-102. Lower scores indicate better condition.


Enrollment: 1812
Study Start Date: April 2007
Estimated Study Completion Date: December 2015
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Paliperidone Extended Release (ER) Drug: Paliperidone ER
Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.

Detailed Description:

This is a non-randomized (the study drug is not assigned by chance), single arm, multicenter (when more than one hospital or medical school team work on a medical research study) 6-month study. Participants can be transitioned to an effective dose of paliperidone ER from any oral antipsychotic medication due to lack of efficacy, lack of tolerability or safety, lack of compliance or other reason. A transition period of maximum 4 weeks will be allowed. Throughout the study, participants will receive flexible dose of 3 to 12 milligram (mg) of paliperidone once daily orally for 6 months. Adjustment of the dosage will be done at Investigator's discretion, based on the individual participant's clinical response and tolerability of the study drug dosages. Participants who complete this 6-month study and would like to continue will be eligible to be enrolled in an extension phase until paliperidone ER is available. The starting dose of the extension phase will be the same as at the end of the 6-month study and may be changed throughout the extension period. The extension phase will consist of a main extension phase (ending with an End of Main Extension Phase Visit) and a modified extension phase (ending with an End of Study Visit). Efficacy will primarily be evaluated by positive and negative syndrome scale (PANSS). Safety will primarily be evaluated by Extrapyramidal Symptom Rating Scale (ESRS).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant meets the Diagnostic and Statistical Manual of Mental Disorders (Edition 4) criteria for schizophrenia
  • Participant is previously non-acute (on the same antipsychotic medication used for the treatment of schizophrenia and Clinical Global Impression-Severity [CGI-S] change less than or equal to 1 in the past 4 weeks before enrollment) and has been given an adequate dose of an appropriate oral antipsychotic for an adequate period of time prior to enrollment, but previous treatment is considered unsuccessful due to one or more of the following reasons: lack of effectiveness, lack of tolerability or safety, lack of compliance and/or other reasons to switch to another antipsychotic medication
  • Participant is healthy on the basis of a physical examination and vital signs at screening
  • Female participants must be postmenopausal for at least 1 year, surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of birth control before entry and throughout the study
  • Participants must be willing and able to fill out self-administered questionnaires

Exclusion Criteria:

  • Participants on clozapine, any conventional depot neuroleptic or risperidone long-acting injection during the last 3 months
  • Participants with serious unstable medical condition, including known clinically relevant laboratory abnormalities
  • Participants with history or current symptoms of tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body) and neuroleptic malignant syndrome (high fever, rigid muscles, shaking, confusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness)
  • Participants judged to be at high risk for adverse events, violence or self-harm
  • Participants with a current use or known history (over the past 6 months) of substance dependence according to Diagnostic and Statistical Manual of Mental Disorders (Edition 4) Criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00460512

  Hide Study Locations
Locations
Belgium
Antwerpen, Belgium
Bertrix, Belgium
Dave, Belgium
Diest, Belgium
Duffel, Belgium
Kortenberg, Belgium
Liège, Belgium
Montignies-Sur-Sambre, Belgium
Mortsel, Belgium
Roeselare, Belgium
Saint-Servais, Belgium
Sint-Truiden, Belgium
St Denijs-Westrem, Belgium
Tielt, Belgium
Waregem, Belgium
Bulgaria
Bulgaria, Bulgaria
Sofia N/A, Bulgaria
Tzerova Korya, Bulgaria
Croatia
Osijek, Croatia
Rijeka, Croatia
Split, Croatia
Zagreb, Croatia
Denmark
Aalborg, Denmark
Helsingør, Denmark
Risskov N/A, Denmark
Viby J, Denmark
Finland
Helsinki, Finland
Raahe, Finland
Tammisaari, Finland
Tampere, Finland
France
Bar Le Duc, France
Bordeaux, France
Bourg En Bresse, France
Bully Les Mines, France
Caen, France
Chambery, France
Clermont Ferrand Cedex 1, France
Creteil Cedex, France
Dijon Cedex, France
Dole, France
Henin Baumont, France
Jarnac, France
La Roche Sur Yon, France
La Seyne Sur Mer, France
Mont St Martin, France
Montpellier, France
Nimes Cedex 9, France
Paris, France
Pau, France
Rennes, France
Roubaix, France
Saint Avé, France
Saint-Cyr Au Mont D'Or N/A, France
Villejuif Cedex, France
Germany
Aalen, Germany
Achim, Germany
Augsburg, Germany
Bamberg, Germany
Bergfelde, Germany
Berlin, Germany
Bochum, Germany
Butzbach, Germany
Coesfeld, Germany
Dillingen, Germany
Dresden, Germany
Duisburg, Germany
Düsseldorf, Germany
Ellwangen, Germany
Elmshorn, Germany
Ettlingen, Germany
Gelnhausen, Germany
Gelsenkirchen, Germany
Gießen, Germany
Göttingen, Germany
Halle, Germany
Hamburg, Germany
Hattingen, Germany
Hemmoor, Germany
Heppenheim, Germany
Idar-Oberstein, Germany
Jena, Germany
Kaufbeuren, Germany
Krefeld, Germany
Köln, Germany
Königsbrück, Germany
Leipzig, Germany
Lüdenscheid, Germany
Mannheim, Germany
Meckel, Germany
Mittweida, Germany
München, Germany
Münster, Germany
Norden, Germany
Nürnberg, Germany
Ober-Ramstadt, Germany
Oldenburg, Germany
Oranienburg, Germany
Ostfildern, Germany
Potsdam, Germany
Schlüchtern, Germany
Siegen, Germany
Stralsund, Germany
Straubing, Germany
Ulm, Germany
Wasserburg, Germany
Wiesbaden, Germany
Wilhelmshaven, Germany
Würzburg, Germany
Greece
Athens, Greece
Chios, Greece
Herakleion, Greece
Larisa, Greece
Thessalonikis, Greece
Hungary
Balassagyarmat N/A, Hungary
Budapest N/A, Hungary
Kecskemet, Hungary
Sopron, Hungary
Israel
Bat-Yam, Israel
Be'Er Ya'Acov, Israel
Jerusalem, Israel
Pardesia, Israel
Latvia
Daugavpils, Latvia
Jelgava, Latvia
Liepaja, Latvia
Riga, Latvia
Strenci, Latvia
Lithuania
Kaunas, Lithuania
Panevezys, Lithuania
Vilnius, Lithuania
Netherlands
'S-Gravenhage, Netherlands
Assen, Netherlands
Beilen, Netherlands
Bennebroek, Netherlands
Enschede, Netherlands
Groningen, Netherlands
Hoofddorp, Netherlands
Leeuwarden, Netherlands
Tilburg, Netherlands
Zwolle, Netherlands
Poland
Bydgoszcz N/A, Poland
Gdynia Na, Poland
Krakow Na, Poland
Lubliniec, Poland
Skorzewo Na, Poland
Portugal
Angra Do Heroísmo, Portugal
Braga, Portugal
Castelo Viegas N/A, Portugal
Coimbra, Portugal
Lisboa, Portugal
Lisboa N/A, Portugal
Porto, Portugal
Porto N/A, Portugal
Russian Federation
Kazan, Russian Federation
Krasnodar, Russian Federation
Moscow, Russian Federation
Moscow N/A, Russian Federation
Moscow Russia, Russian Federation
Saint-Petersburg, Russian Federation
Saratov, Russian Federation
St Peterburg Na, Russian Federation
St Petersburg, Russian Federation
Yaroslavl, Russian Federation
Serbia
Beograd, Serbia
Kragujevac, Serbia
Novi Sad, Serbia
Spain
Alicante, Spain
Barcelona, Spain
Bunyola Illes Balears, Spain
Burgos, Spain
Oviedo, Spain
Pontevedra, Spain
Sama De Langreo Asturias, Spain
Valencia, Spain
Zamora, Spain
Zaragoza, Spain
Sweden
Bromma, Sweden
Göteborg, Sweden
Hudiksvall, Sweden
Karlskrona, Sweden
Malmö, Sweden
Mölndal, Sweden
Norrtälje, Sweden
Nyköping, Sweden
Simrishamn, Sweden
Skövde, Sweden
Solna, Sweden
Trollhättan, Sweden
Västra Frölunda, Sweden
Switzerland
Aarau, Switzerland
Basel Bs, Switzerland
Bienne, Switzerland
Geneve, Switzerland
Lenzburg, Switzerland
Montreux, Switzerland
Oetwil Am See, Switzerland
Riehen, Switzerland
Solothurn, Switzerland
Viganello, Switzerland
Zürich, Switzerland
Turkey
Ankara N/A, Turkey
Denizli, Turkey
Diyarbakir, Turkey
Gaziantep, Turkey
Izmir, Turkey
United Kingdom
Barnet, United Kingdom
Birmingham, United Kingdom
Clacton On Sea, United Kingdom
Devon, United Kingdom
Exeter, United Kingdom
Glasgow, United Kingdom
Sponsors and Collaborators
Janssen-Cilag International NV
Investigators
Study Director: Janssen-Cilag International NV Clinical Trial Janssen-Cilag International NV
  More Information

Additional Information:
No publications provided by Janssen-Cilag International NV

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Janssen-Cilag International NV
ClinicalTrials.gov Identifier: NCT00460512     History of Changes
Other Study ID Numbers: CR012949, R076477SCH3017, 2006-004265-34
Study First Received: April 13, 2007
Last Updated: June 13, 2014
Health Authority: Croatia: Ministry of Health
France: The French National Agency for Medicines and Health Products
Germany: Ethics Commission
Lithuania: State Medicine Control Agency - Ministry of Health

Keywords provided by Janssen-Cilag International NV:
Schizophrenia
Flexible dosing
Non-acute patients
Antipsychotic
Atypical
INVEGA

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Antipsychotic Agents
9-hydroxy-risperidone
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on July 24, 2014